Background: Allergic contact dermatitis (ACD) is an inflammatory skin disease caused by repeated skin exposure to contact allergens. The severity and duration of this disease are associated with many different factors. Some of these factors may represent markers for monitoring disease activity and the individual response to an intervention. Methods: We used a targeted metabolomics approach to find such factors in the serum of individuals with ACD. Metabolomics profiles were examined and compared in the acute phase of the disease and also in the absence of disease activity. Results: Our study identified a significant remission phase of ACD-associated systemic biochemical shifts in 2 metabolic pathways: tryptophan-kynurenine and phenylalanine-tyrosine. Conclusions: Although the responsible mechanisms are unclear, these results suggest that the remission phase of ACD is linked to tryptophan metabolism via kynurenine and phenylalanine-tyrosine pathways. However, further replication studies with a larger number of subjects and their subgroups are necessary to validate our results. These studies may provide a new perspective with which to understand the mechanism of and find potential biomarkers of ACD, as well as a new reference for personalized treatment.

Keywords:
Allergic contact dermatitis, Metabolites, Tryptophan, Phenylalanine
1.
Thyssen JP, Linneberg A, Menne T, Johansen JD: The epidemiology of contact allergy in the general population - prevalence and main findings. Contact Dermatitis 2007;57:287-299.
2.
Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF: Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 2009;64:1699-1714.
3.
Sharon D, Chen R, Snyder M: Systems biology approaches to disease marker discovery. Dis Markers 2010;28:209-224.
4.
Li S, Todor A, Luo R: Blood transcriptomics and metabolomics for personalized medicine. Comput Struct Biotechnol J 2016;14:1-7.
5.
Huang Y, Chen G, Liu X, Shao Y, Gao P, Xin C, Cui Z, Zhao X, Xu G: Serum metabolomics study and eicosanoid analysis of childhood atopic dermatitis based on liquid chromatography-mass spectrometry. J Proteome Res 2014;13:5715-5723.
6.
White JM: Patch testing: what allergists should know. Clin Exp Allergy 2012;42:180-185.
7.
Nikkanen J, Forsstrom S, Euro L, Paetau I, Kohnz RA, Wang L, Chilov D, Viinamaki J, Roivainen A, Marjamaki P, Liljenback H, Ahola S, Buzkova J, Terzioglu M, Khan NA, Pirnes-Karhu S, Paetau A, Lonnqvist T, Sajantila A, Isohanni P, Tyynismaa H, Nomura DK, Battersby BJ, Velagapudi V, Carroll CJ, Suomalainen A: Mitochondrial DNA replication defects disturb cellular dNTP pools and remodel one-carbon metabolism. Cell Metab 2016;23:635-648.
8.
Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, Lowry CA: Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med 2006;8:1-27.
9.
Miyamoto S, Taylor SL, Barupal DK, Taguchi A, Wohlgemuth G, Wikoff WR, Yoneda KY, Gandara DR, Hanash SM, Kim K, Fiehn O: Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography time-of-flight mass spectrometry. Metabolites 2015;5:192-210.
10.
Cui L, Lee YH, Kumar Y, Xu F, Lu K, Ooi EE, Tannenbaum SR, Ong CN: Serum metabolome and lipidome changes in adult patients with primary dengue infection. PLoS Negl Trop Dis 2013;7:e2373.
11.
Oxenkrug GF: Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann NY Acad Sci 2007;1122:35-49.
12.
Guillemin GJ, Brew BJ: Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep 2002;7:199-206.
13.
Guillemin GJ, Kerr SJ, Brew BJ: Involvement of quinolinic acid in aids dementia complex. Neurotox Res 2005;7:103-123.
14.
Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW, Darlington LG: Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 2005;93:611-623.
15.
Takikawa O: Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem Biophys Res Commun 2005;338:12-19.
16.
Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC: Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007;67:7082-7087.
17.
Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL: Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-1372.
18.
Bianchi M, Bertini R, Ghezzi P: Induction of indoleamine dioxygenase by interferon in mice: a study with different recombinant interferons and various cytokines. Biochem Biophys Res Commun 1988;152:237-242.
19.
Robinson CM, Hale PT, Carlin JM: The role of IFN-γ and TNF-α-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 2005;25:20-30.
20.
Ramanathan A, Wang C, Schreiber SL: Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 2005;102:5992-5997.
21.
Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M: An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011;478:197-203.
22.
Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA: An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010;185:3190-3198.
23.
Thaker AI, Rao MS, Bishnupuri KS, Kerr TA, Foster L, Marinshaw JM, Newberry RD, Stenson WF, Ciorba MA: IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology 2013;145:416-425.e1-4.
24.
Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P: Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008;111:2152-2154.
25.
Carley DW, Radulovacki M: Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat. Am J Respir Crit Care Med 1999;160:1824-1829.
26.
Kim TD, Kim JS, Kim JH, Myung J, Chae HD, Woo KC, Jang SK, Koh DS, Kim KT: Rhythmic serotonin n-acetyltransferase mRNA degradation is essential for the maintenance of its circadian oscillation. Mol Cell Biol 2005;25:3232-3246.
27.
Soga F, Katoh N, Inoue T, Kishimoto S: Serotonin activates human monocytes and prevents apoptosis. J Invest Dermatol 2007;127:1947-1955.
28.
Ghia JE, Li N, Wang H, Collins M, Deng Y, El-Sharkawy RT, Cote F, Mallet J, Khan WI: Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 2009;137:1649-1660.
29.
Loo YH: Serotonin deficiency in experimental hyperphenylalaninemia. J Neurochem 1974;23:139-147.
30.
Martinez A, Knappskog PM, Olafsdottir S, Doskeland AP, Eiken HG, Svebak RM, Bozzini M, Apold J, Flatmark T: Expression of recombinant human phenylalanine hydroxylase as fusion protein in Escherichia coli circumvents proteolytic degradation by host cell proteases: isolation and characterization of the wild-type enzyme. Biochem J 1995;306(pt 2):589-597.
31.
Hirobe T: Structure and function of melanocytes: microscopic morphology and cell biology of mouse melanocytes in the epidermis and hair follicle. Histol Histopathol 1995;10:223-237.
32.
Hiramoto K, Kobayashi H, Ishii M, Sato E, Inoue M: Increased α-melanocyte-stimulating hormone (α-MSH) levels and melanocortin receptors expression associated with pigmentation in an NC/Nga mouse model of atopic dermatitis. Exp Dermatol 2010;19:132-136.
33.
Slominski A, Costantino R: Molecular mechanism of tyrosinase regulation by L-DOPA in hamster melanoma cells. Life Sci 1991;48:2075-2079.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.